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The molecular changes for tumorigenesis in meningiomas are
only half known. In general, there are three approaches to
investigations: analysing the genetic changes required for
tumorigenesis, studying syndromes of familial brain tumours
that may include meningiomas, and investigating specific
genetic defects that may correlate with tumour grade and
clinical behaviour.
For the first aim, a wide variety of techniques, from conven-
tional molecular techniques to newer techniques such as com-
parative genomic hybridization and expression microarray,
have been used. The only confirmed tumour-associated gene
in meningioma is the neurofibromatosis 2 gene (NF2) located
on chromosome 22q12. About 60% of sporadic meningiomas
exhibit either mutations in NF2 or deletions in 22q or even
monosomy and, in many instances, nicely follow the two-hit
model of tumour suppressor gene inactivation.1 A meningi-
oma-prone NF2 knockout mouse was recently developed and
will serve as a useful model for testing novel therapies.2 Allelic
loss has also been documented in 1p, 10q, 14q, 6q, 9q, 17q and
18q. These regions may harbour potential tumour suppressor
sites that need to be delineated. Recent studies are highly
suggestive that another protein 4.1 family member (the NF2
product, merlin being one), 4.1R encoded by a gene at 1p36, is
a tumour suppressor.3 So far, no known oncogene has been
identified for meningiomas. In spite of the small proportion of
cases with 17p loss, studies of the p53 gene have not shown
significant gene alterations, a finding similar to that of Das et
al in this issue of the Asian Journal of Surgery. It has been clear to
most investigators in this field that the p53 gene is not a major
gene of interest; few benign tumours elsewhere possess p53
mutations. Meningiomas occur in both type 1 (NF1) and type
2 neurofibromatosis for which germline mutations play a
major role in tumorigenesis. As NF1 is a very large gene, it has,
so far, not been studied in sporadic meningiomas, although
aberrant splicing has been suggested as a mechanism of
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reduced expression.4
A number of cytogenetic or molecular abnormalities are
associated with meningioma progression or high-grade
histology. In most instances, the relevant candidate genes
remain a mystery. For example, 14q deletions are common in
high-grade meningiomas or meningiomas that subsequently
recur5 and the loss of the p16 gene on 9p21 is associated with
anaplastic meningiomas and poor survival.6–9 The powerful
technique of expression profiling used to examine thousands
of genes simultaneously has also been used with meningiomas,
but it remains to be seen whether it will yield useful data
towards patient prognosis or management.10
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